Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: January 13, 2014
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)